XENE Q4 2024 Earnings — Xenon Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

XENEXenon Pharmaceuticals Inc.

$5B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$77M

Net Income

-$66M

EPS (Diluted)

$-0.84

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$55M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$798M

Total Liabilities

$43M

Stockholders' Equity

$755M

Cash & Equivalents

$143M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$77M	-$54M	-44.3%
Net Income	-$66M	-$45M	-46.8%